Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mosipasertib (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Appendiceal cancer; Colon cancer; Colorectal cancer; Duodenal neoplasms; Endometrial cancer; Fallopian tube cancer; Male breast cancer; Merkel cell carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms ABOYA-119
  • Sponsors Aprea Therapeutics; Atrin Pharmaceuticals

Most Recent Events

  • 12 Aug 2026 According to an Aprea Therapeutics media release, company is considering future combination development of ATRN-119 with immune-oncology agents, chemotherapy, ADCs, and/or radiation therapy, and is currently discussing potential combination studies with leading academic centers. Potential indications include advanced solid tumors such as HPV-positive head and neck cancer, sarcoma, ovarian, colorectal, and lung cancers, as well as hematologic malignancies.
  • 12 Aug 2026 According to an Aprea Therapeutics, ABOYA-119 phase 1/2a dose-escalation study of ATRN-119 completed dose escalation and established an RP2D of 1,100 mg once daily in 2025. The study was subsequently closed as the company shifted resources toward APR-1051.
  • 04 Aug 2026 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top